Bo Chen
Harbin Medical University
16 Papers
6 Citations
Bo Chen is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Cancer & Pharmacogenomics. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer
Zhangxiang Zhao,Yingying Guo,Yaoyao Liu,Lichun Sun,Bo Chen,Chengyu Wang,Tingting Chen,Yuquan Wang,Yawei Li,Qi Dong,Liqiang Ai,Ran Wang,Yunyan Gu,Xia Li +13 more
TL;DR: Zhang et al. as discussed by the authors constructed an individualized differentially expressed lncRNA (IDElncRNA) profile for breast invasive carcinoma (BRCA) using the method of LncRNA Individualization (LncRIndiv).
RHPCG: a database of the Regulation of the Hippo Pathway in Cancer Genome.
Chengyu Wang,Fan Yang,Tingting Chen,Qi Dong,Zhangxiang Zhao,Yaoyao Liu,Bo Chen,Haihai Liang,Huike Yang,Yunyan Gu +9 more
TL;DR: The Regulation of the Hippo Pathway in Cancer Genome (RHPCG) database is a powerful tool that could help researchers understand gene alterations and regulatory mechanisms in the HippO signaling pathway in cancer.
9
Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer
Yawei Li,Zhangxiang Zhao,Liqiang Ai,Yuquan Wang,Kaidong Liu,Bo Chen,Tingting Chen,Shuping Zhuang,Huanhuan Xu,Min Zou,Yunyan Gu,Xia Li +11 more
TL;DR: Wang et al. as mentioned in this paper developed a transcriptional homologous recombination defectiveness (HRDness) signature, comprising 16 gene pairs (16-GPS), for prostate cancer by a relative expression ordering (REO)-based discovery procedure.
9
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade
Ting Chen,Tong Yu,Shuping Zhuang,Yiding Geng,Jun-Tian Xue,Jiayi Wang,Liqiang Ai,Bo Chen,Zhangxiang Zhao,Yawei Li,Jinghao Wang,Haihai Liang,Yan Xu,Yunyan Gu +13 more
TL;DR: 2-GPS could robustly predict BRCAness OvCa at the individual level and extend the population who may benefit from PARP inhibitors.
7
Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.
Qi Dong,Tong Yu,Bo Chen,Mingyue Liu,Xiang Sun,Hui Cao,Kai Liu,Huanhuan Xu,Yuquan Wang,Shuping Zhuang,Zixin Jin,Haihai Liang,Yang Hui,Yunyan Gu +13 more
TL;DR: It is suggested that RB1 mutation mediates the sensitivity to PARPis through a synthetic lethal effect by triggering the cGAS/STING pathway and upregulation of immune infiltration in LUAD, which may be a potential therapeutic strategy.
6